As the cell and gene therapy field matures, so does the demand for viral vector manufacturing, in particular for lentivirus (LV) and adeno-associated virus (AAV) production, two governing vectors used for both ex vivo and in vivo gene therapies. While searching for a successful manufacturing platform, the definitive objective of therapeutics developers is to help ensure the manufacturing process is commercially feasible. Commercial viability is tied to both the quality of the manufacturing process acceptable for regulators and cost of virus per patient, justifiable for the business as a percent of the overall cost of goods and services. The latter is closely related to process scalability.
When addressing the question of commercial viability, drug developers face a crucial question: what option is better - the adherent or suspension viral vector manufacturing process?
In adherent cell culture, cells are grown while attached to a substrate as monolayers. In suspension cell culture, cells are free floating in the culture medium. So which offers more benefits? Let’s dive. In.